Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
“Intestinal toxins” collectively refer to harmful substances produced or released in the intestinal environment, often as microbial fermentation products or as cell wall components such as lipopolysaccharide (LPS, also called endotoxin). These molecules, which can include endotoxins, enterotoxins, and secondary bile acids, can impair gut barrier function, provoke immune responses, and are linked to a variety of diseases including sepsis, metabolic syndrome, chronic inflammation, and more. Some well-characterized examples are bacterial LPS (endotoxin), cholera toxin, and bacterial secondary bile acids, all of which affect intestinal or systemic physiology by activating immune pathways, triggering inflammation, or causing direct cellular injury[1][5][6]. This category is overly broad and not a specific druggable or molecular entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intestinal toxins.